Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
Pathos AI’s Acquisition of Rain Oncology
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
Avadel Pharmaceuticals’ $75 Million Royalty Financing
Goodwin Procter advised Avadel Pharmaceutics on the deal. Avadel announced its royalty agreement with RTW Investments, LP and certain of its affiliates for up to $75 million....
ImmunityBio’s $50.0 Million Offering
Goodwin Procter advised Jefferies LLC as exclusive placement agent on the deal. ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced that it has executed financing...
Entrada Therapeutics’ Global Collaboration with Vertex Pharmaceuticals Incorporated
Goodwin Procter advised Entrada Therapeutics, Inc. on the deal. Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to focus...
ACELYRIN’s $300 Million Series C Financing Round
Goodwin Procter advised ACELYRIN on the deal. ACELYRIN announced the completion of its $300 million Series C financing round which was led by Access Biotechnology with participation...
Medipost Co.’s Agreement with OmniaBio
Goodwin Procter advised Medipost Co. on the deal. Medipost Co. announced its strategic agreement with OmniaBio, Inc., a subsidiary of the Centre for Commercialization of Regenerative Medicine...
Blueprint Medicines Corporation’s Financing Collaborations with Sixth Street and Royalty Pharma
Goodwin Procter advised Blueprint Medicines Corporation on the deal while Cooley represented Sixth Street. Blueprint Medicines Corporation (NASDAQ: BPMC) announced its strategic financing collaborations with Sixth...
AbCellera’s Acquisition of TetraGenetics
Goodwin Procter advised AbCellera on the deal. AbCellera (Nasdaq: ABCL) announced its acquisition of TetraGenetics. AbCellera is a technology company with a centralized operating system for next-generation...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...